What is ARX Sciences?
ARX Sciences operates as a critical supplier of high-purity immunological reagents, including a comprehensive portfolio of proteins, primary and secondary antibodies, and specialized transport media. The company distinguishes itself through rigorous validation protocols and adherence to GMP manufacturing standards, which are essential for maintaining the integrity of diagnostic and research workflows. Beyond its product catalog, ARX Sciences provides flexible contract manufacturing services, offering custom quality testing that caters to the nuanced requirements of the research and diagnostic industries. This dual-model approach—combining high-quality reagent supply with bespoke manufacturing solutions—positions the company as a vital partner for organizations navigating complex biological research and clinical diagnostic development.
How much funding has ARX Sciences raised?
ARX Sciences has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2024): $350K with participation from Bank of America
Key Investors in ARX Sciences
Bank of America
A global financial institution providing comprehensive banking and investment services, often supporting large-scale corporate growth through debt financing and strategic capital allocation.
What's next for ARX Sciences?
With the infusion of this late-stage capital, ARX Sciences is expected to prioritize the scaling of its manufacturing infrastructure and the enhancement of its quality assurance frameworks. The strategic focus will likely shift toward increasing production capacity for viral and liquid transport media, as well as expanding its reach into emerging diagnostic markets. By optimizing its supply chain and investing in advanced validation technologies, the company aims to solidify its reputation as a reliable, high-standard provider of essential biological tools. Future growth will be driven by the continued demand for high-purity reagents in both academic research and commercial diagnostic applications, ensuring that ARX Sciences remains at the forefront of the life sciences supply chain.
See full ARX Sciences company page
